Sign in
4

Changes in Ownership

PROVECTUS BIOPHARMACEUTICALS, INC. Filed Acc 0001641172-25-016049

Options or other derivatives

  • CEO acquired 0 shares (option exercise)
  • CEO acquired 18,880 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
Pershing Edward CEO 2025-06-20 Option exercise · 8% Unsecured Convertible Promissory Note −0 D: show line 1 in the form
Pershing Edward CEO 2025-06-20 Option exercise · Series D-1 Convertible Preferred Stock +18,880 2,110,732 D: show line 2 in the form
Loading xslF345X05/ownership.xml…